Table 1_Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breas

A single-case medical report details a 39-year-old patient with a 14.3 cm ulcerated triple-negative breast cancer. The report, authored by Jie Tan and uploaded to figshare in March 2026, describes a multimodal treatment approach combining transarterial chemoembolization (TACE) with systemic nab-paclitaxel and the PD-1 inhibitor Toripalimab, resulting in a pathological complete response.

Use Cases

• Analyze a multimodal treatment sequence for locally advanced breast cancer based on the described combination of TACE and systemic chemo-immunotherapy.
• Study the feasibility of achieving a pathological complete response in a single patient with a giant, ulcerated tumor based on the reported Miller-Payne grade 5 outcome.
• Investigate potential synergistic immune activation from combining TACE with a PD-1 inhibitor as suggested in the report's discussion.
• Review a detailed clinical case for educational or hypothesis-generating purposes based on the comprehensive narrative of patient presentation, treatment, and outcome.

Strengths

• Report provides specific clinical details, including patient age (39), tumor size (14.3 cm), and pathological outcome (Miller-Payne grade 5, ypT0N0M0).
• The dataset is openly licensed under CC-BY-4.0, permitting reuse with attribution.
• The file was last updated on 2026-03-17, indicating recent availability.

Limitations

• The dataset is a single-case report (19.3 KB), which limits statistical power and generalizability.
• Column-level documentation is absent; field semantics must be inferred from the narrative text.
• Data may reflect the specific clinical context of a single patient, which may not be representative of broader populations.

Provenance

Source

figshare, authored by Jie Tan.

Collection Method

Clinical case documentation.

Freshness

Last updated 2026-03-17 13:07:54.